Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib.

Adult Aged Aged, 80 and over Antineoplastic Agents / therapeutic use Arterial Occlusive Diseases / blood Cholesterol / blood Dyslipidemias / blood Female Humans Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood Lipoproteins, LDL / blood Male Middle Aged Pyrimidines / therapeutic use Risk Factors Young Adult

Arterial occlusive event Cholesterol Chronic myeloid leukemia LDL Nilotinib Triglycerides

Journal

Annals of hematology

ISSN: 1432-0584

Titre abrégé: Ann Hematol

Pays: Germany

ID NLM: 9107334

Informations de publication

Date de publication:
Aug 2021

Historique:

received: 26 10 2020

accepted: 21 12 2020

pubmed: 4 1 2021

medline: 29 7 2021

entrez: 3 1 2021

Statut: ppublish

Résumé

Recommendations for dyslipidemia management aimed at reducing arterial occlusive events (AOEs) have been recently published. So far, no data have been reported on the management of dyslipidemia in chronic myeloid leukemia (CML) patients treated with nilotinib. We investigated 369 CML adult patients, stratified according to the new Systematic Coronary Risk Evaluation (SCORE) scoring system. Plasma levels of cholesterol, HDL, LDL, and triglycerides were measured prior to the start of nilotinib and after 3, 6, and 12 months. The 5-year cumulative incidence of AOEs was 15.9%. Patients with cholesterol levels > 200 mg/dL and LDL > 70 mg/dL 3 months after treatment showed a significantly higher incidence of AOEs (21.9 ± 4.6% vs 6.2 ± 2.5, P = 0.003). Patients belonging to the high and very high SCORE risk group showed a significant increase of AOEs (34.4 ± 6% vs 10 ± 2.1%, P < 0.001). In multivariate analysis, both high cholesterol and LDL levels and a high and very high SCORE risk remained significantly associated with the risk of AOEs (P = 0.008; HR = 3.5; 95% CI = 1.4-8.7 and P < 0.001; HR = 4.4; 95% CI = 2-9.8, respectively). Overall, 78 patients (21.1%) presented dyslipidemia at the time of CML diagnosis and 88 (23.3%) after starting nilotinib, but only 26 of them (29.5%) were treated with statins.Low LDL and cholesterol plasma levels are associated with a significant lower risk of AOEs in CML patients treated with nilotinib in the real life.

Identifiants

DOI: 10.1007/s00277-020-04392-w PMID: 33388860

pubmed: 33388860

doi: 10.1007/s00277-020-04392-w

pii: 10.1007/s00277-020-04392-w

doi:

Substances chimiques

Antineoplastic Agents 0

Lipoproteins, LDL 0

Pyrimidines 0

Cholesterol 97C5T2UQ7J

nilotinib F41401512X

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

2005-2014

Subventions

Organisme : P.O.R. SARDEGNA F.S.E. 2014-2020

ID : Istruzione e Formazione, Obiettivo Tematico: 10, Obiettivo Specifico: 10.5, Azione dell'accordo fi Partenariato:10.5.12

Commentaires et corrections

Type : CommentIn

Informations de copyright

Références

Sacha T, Saglio G (2019) Nilotinib in the treatment of chronic myeloid leukemia. Future Oncol 15(9):953–965

doi: 10.2217/fon-2018-0468

Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim D-W, Issaragrisil S, le Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, Menssen HD, Kantarjian HM (2016) Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 30(5):1044–1054

doi: 10.1038/leu.2016.5

Aghel N, Lipton JH, Atenafu EG, Kim DDH, Delgado DH (2017) Cardiovascular events after exposure to nilotinib in chronic myeloid leukemia: long-term follow-up. Clin Lymphoma Myeloma Leuk 17(12):870–878.e1

doi: 10.1016/j.clml.2017.07.006

Bondon-Guitton E, Combret S, Pérault-Pochat MC, Stève-Dumont M, Bagheri H, Huguet F, Despas F, Pathak A, Montastruc JL (2016) Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy. Target Oncol 11(4):549–552

doi: 10.1007/s11523-016-0417-x

Caocci G, Mulas O, Annunziata M, Luciano L, Bonifacio M, Orlandi EM, Pregno P, Galimberti S, Russo Rossi A, Abruzzese E, Iurlo A, Martino B, Sgherza N, Binotto G, Castagnetti F, Gozzini A, Fozza C, Bocchia M, Sicuranza A, Stagno F, Efficace F, Usala E, de Gregorio F, Scaffidi L, Elena C, Pirillo F, Baratè C, Trawinska MM, Cattaneo D, Labate C, Gugliotta G, Molica M, Specchia G, la Nasa G, Foà R, Breccia M (2018) Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: identification of risk factors and the role of prophylaxis. Am J Hematol 93(7):E159–E161

doi: 10.1002/ajh.25102

Caocci G, Mulas O, Bonifacio M, Abruzzese E, Galimberti S, Orlandi EM et al (2019) Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. Int J Cardiol 288:124–127

doi: 10.1016/j.ijcard.2019.04.051

Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgözoğlu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL (2017) Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur Heart J 38(32):2459–2472

doi: 10.1093/eurheartj/ehx144

Ko C-W, Qu J, Black DD, Tso P (2020) Regulation of intestinal lipid metabolism: current concepts and relevance to disease. Nat Rev Gastroenterol Hepatol 17(3):169–183

doi: 10.1038/s41575-019-0250-7

Tabas I, Williams KJ, Borén J (2007) Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 116(16):1832–1844

doi: 10.1161/CIRCULATIONAHA.106.676890

Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL et al (2016) 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 37(29):2315–2381

doi: 10.1093/eurheartj/ehw106

Authors/Task Force Members, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies (2019) 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 290:140–205

doi: 10.1016/j.atherosclerosis.2019.08.014

Medical Dictionary for Regulatory Activities Terminology (MedDRA) - Summary | NCBO BioPortal [Internet]. [cited 2020 Nov 21]. Available from: http://bioportal.bioontology.org/ontologies/MEDDRA

Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia.

Cross NCP, White HE, Müller MC, Saglio G, Hochhaus A (2012) Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 26(10):2172–2175

doi: 10.1038/leu.2012.104

Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP [Internet]. [cited 2020 Mar 11]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50

Caocci G, Atzeni S, Orrù N, Azzena L, Martorana L, Littera R, Ledda A, la Nasa G (2008) Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia. Leukemia. 22(11):2127–2128

doi: 10.1038/leu.2008.106

Steegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A, Kim DW, Kim TD, Khoury HJ, le Coutre P, Mayer J, Milojkovic D, Porkka K, Rea D, Rosti G, Saussele S, Hehlmann R, Clark RE (2016) European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 30(8):1648–1671

doi: 10.1038/leu.2016.104

Iurlo A, Orsi E, Cattaneo D, Resi V, Bucelli C, Orofino N, Sciumè M, Elena C, Grancini V, Consonni D, Orlandi EM, Cortelezzi A (2015) Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem? Oncotarget. 6(32):33944–33951

doi: 10.18632/oncotarget.5580

Rea D, Mirault T, Cluzeau T, Gautier J-F, Guilhot F, Dombret H, Messas E (2014) Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. Haematologica. 99(7):1197–1203

doi: 10.3324/haematol.2014.104075

Yu L, Liu J, Huang X, Jiang Q (2019) Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase. Sci Rep 9(1):17601

doi: 10.1038/s41598-019-54033-0

Horňák T, Semerád L, Žáčková D, Weinbergerová B, Šustková Z, Procházková J, Bělohlávková P, Stejskal L, Rohoň P, Faber E, Žák P, Mayer J, Ráčil Z (2020) Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients - results from real-life prospective study. Leuk Lymphoma 61(2):494–496

doi: 10.1080/10428194.2019.1672054

Ashry NA, Abdеlaziz RR, Suddеk GM (2020) The potential effect of imatinib against hypercholesterolemia induced atherosclerosis, endothelial dysfunction and hepatic injury in rabbits. Life Sci 243:117275

doi: 10.1016/j.lfs.2020.117275

Pouwer MG, Pieterman EJ, Verschuren L, Caspers MPM, Kluft C, Garcia RA, Aman J, Jukema JW, Princen HMG (2018) The BCR-ABL1 inhibitors imatinib and ponatinib decrease plasma cholesterol and atherosclerosis, and nilotinib and ponatinib activate coagulation in a translational mouse model. Front Cardiovasc Med 5:55

doi: 10.3389/fcvm.2018.00055

Alhawiti N, Burbury KL, Kwa FA, O’Malley CJ, Shuttleworth P, Alzard M et al (2016) The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state. Thromb Res 145:54–64

doi: 10.1016/j.thromres.2016.07.019

Borén J, Williams KJ (2016) The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol 27(5):473–483

doi: 10.1097/MOL.0000000000000330

Caocci G, Mulas O, Abruzzese E, Luciano L, Iurlo A, Attolico I, Castagnetti F, Galimberti S, Sgherza N, Bonifacio M, Annunziata M, Gozzini A, Orlandi EM, Stagno F, Binotto G, Pregno P, Fozza C, Trawinska MM, de Gregorio F, Cattaneo D, Albano F, Gugliotta G, Baratè C, Scaffidi L, Elena C, Pirillo F, Scalzulli E, la Nasa G, Foà R, Breccia M (2019) Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the systematic coronary risk evaluation (SCORE) chart. Hematol Oncol 37(3):296–302

doi: 10.1002/hon.2606

Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267–1278

doi: 10.1016/S0140-6736(05)67394-1

Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, Kahn J, Afonso L, Williams KA Sr, Flack JM (2012) Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol 60(25):2631–2639

doi: 10.1016/j.jacc.2012.09.017

Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Hólm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart AFR, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett MS, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki ML, Perola M, Havulinna A, de Faire U, Gigante B, Ingelsson E, Zeller T, Wild P, de Bakker PIW, Klungel OH, Maitland-van der Zee AH, Peters BJM, de Boer A, Grobbee DE, Kamphuisen PW, Deneer VHM, Elbers CC, Onland-Moret NC, Hofker MH, Wijmenga C, Verschuren WMM, Boer JMA, van der Schouw YT, Rasheed A, Frossard P, Demissie S, Willer C, Do R, Ordovas JM, Abecasis GR, Boehnke M, Mohlke KL, Daly MJ, Guiducci C, Burtt NP, Surti A, Gonzalez E, Purcell S, Gabriel S, Marrugat J, Peden J, Erdmann J, Diemert P, Willenborg C, König IR, Fischer M, Hengstenberg C, Ziegler A, Buysschaert I, Lambrechts D, van de Werf F, Fox KA, el Mokhtari NE, Rubin D, Schrezenmeir J, Schreiber S, Schäfer A, Danesh J, Blankenberg S, Roberts R, McPherson R, Watkins H, Hall AS, Overvad K, Rimm E, Boerwinkle E, Tybjaerg-Hansen A, Cupples LA, Reilly MP, Melander O, Mannucci PM, Ardissino D, Siscovick D, Elosua R, Stefansson K, O'Donnell CJ, Salomaa V, Rader DJ, Peltonen L, Schwartz SM, Altshuler D, Kathiresan S (2012) Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380(9841):572–580

doi: 10.1016/S0140-6736(12)60312-2

Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA, Kopecky SL, Baccara-Dinet MT, du Y, Pordy R, Gipe DA (2015) Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol 9(6):758–769

doi: 10.1016/j.jacl.2015.08.006

Keating AJ, Campbell KB, Guyton JR (2013) Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy. Ann Pharmacother 47(3):398–404

doi: 10.1345/aph.1R509